Abstract: A fungicidal agent of the formula: ##STR1## or a pharmaceutically or agriculturally acceptable salt thereof, wherein R is 5-chloropyrid-2-yl or a phenyl group optionally substituted by 1 to 3 substituents each independently selected from F, Cl, Br, I, CF.sub.3, C.sub.1 -C.sub.4 alkyl and C.sub.1 -C.sub.4 alkoxy;and ##STR2## where n is 0, 1, 2 or 3 and R.sup.2 is H or C.sub.1 -C.sub.4 alkyl.

Abstract: An .alpha.-fluoroalkyl carboxylic acid ester of the general formula ##STR1## wherein A is R.sup.1 R.sup.2 COR.sup.3 -- or R.sup.4 CO--, wherein R.sup.1 and R.sup.2 are independently hydrogen, alkyl, alkoxyl or phenyl, with or without the formation of a common ring therebetween, R.sup.3 is hydrogen or alkyl, R.sup.4 and R are independently alkyl, and R.sub.f is fluoroalkyl. The .alpha.-fluoroalkyl carboxylic acid ester is prepared by reacting a fluoroalkyl silyl ketene acetal of the formula ##STR2## wherein R' is alkyl and R.sub.f and R are the same as defined above, with the corresponding acetal, ketone or acyl halide.

Abstract: A colorless liquid crystalline compound having at least one 6-membered ring and non-cyclic end groups in the molecular skelton, said 6-membered containing two or more carbon atoms, at least one of which is directly bonded to a methylene group of a non-cyclic group having an alkoxy group at another end has a wide mesomorphic range. When said colorless liquid crystalline compound is mixed with a liquid crystal composition, the resulting mixture also has an enlarge mesomorphic range and in almost all cases has a reduced viscosity.

Abstract: A method of producing alkyl 3-hydroxy-4-(4-hydroxyphenoxy)pentanoate which comprises the steps of: (a) reacting 4-benzyloxyphenol with an alkali hydroxide and 2-chloropropionic acid in the presence of a suitable solvent and at a temperature sufficient to cause formation of 2-(4-benzyloxyphenoxy)propionic acid; (b) reacting said 2-(4-benzyloxyphenoxy)propionic acid with a compound selected from phosgene, oxalyl chloride, thionyl chloride, or phosphorus trichloride, in the presence of a suitable catalyst and solvent and at a temperature sufficient to cause formation of 2-(4-benzyloxyphenoxy)propionyl chloride; (c) reacting said 2-(4-benzyloxyphenoxy)propionyl chloride with 2,2-dimethyl-1,3-dioxan-4,6-dione and pyridine, all in the presence of a suitable solvent and at a temperature sufficient to cause formation of 5-[2-(4-benzyloxyphenoxy)propionyl]-2,2-dimethyl-1,3-dioxan-4,6-dione; (d) reacting said 5-[2-(4-benzyloxyphenoxy)propionyl]-2,2-dimethyl-1,3-dioxan-4,6-dione with an alkyl alcohol for a period of tim

Abstract: An alkyl 3-hydroxy-4-(4-hydroxyphenoxy)pentanoate having the formula ##STR1## wherein R is an alkyl or substituted alkyl group ranging from about 1 to about 18 carbon atoms.

Abstract: The invention relates to nematic liquid crystals in electro-optical components for the modulation of light as well as for the representation of numerals, signs and images and to a method for producing the same.It is the object of the invention to create nematic liquid crystals which are well suited for electro-optical devices, preferably for two-frequency operation.It has been found that pure or mixed 2-n-alkyl-1, 4-bis-[4-acyloxy]-benzenes of the general formula ##STR1## wherein R.sup.3 =n-C.sub.m H.sub.2m+1, with m=3 to 14, are well suited for utilization in electro-optical components.It was found that 2-n-alkyl-1,4-bis-[acyloxy]-benzene which is well suited for electro-optical components, and especially for two-frequency operations, can be produced by the conversion of a correspondingly substituted benzoic acid or cyclohexane carboxylic acid or a reaction-capable derivative thereof with the corresponding 2-n-alkylhydroquinone--also in the form of its phenylate--at a temperature ranging from 0.degree. C.

Abstract: Compounds useful as plant growth regulators and fungicides and having the formula ##STR1## and stereoisomers thereof, wherein W is --CH.dbd. or .dbd.N--; Q is optionally substituted aryl, especially optionally substituted phenyl, or optionally substituted aralkyl or alkyl; R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6, which may be the same or different, are H, optionally substituted alkyl, cycloalkyl, aralkyl or phenyl; R.sup.7 and R.sup.8 are H, alkyl or optionally substituted phenyl; and acid addition salts and metal complexes thereof, and processes and intermediates for their preparation.

Abstract: The present invention provides substantially difunctional hydroxyl-terminated polyether-esters and a process for preparing the same. The process comprises reacting ethylene carbonate with a substituted or unsubstituted epsilon-caprolactone in the presence of a catalytic amount of a specified catalyst at a temperature of at least about 200.degree. C. The catalyst comprises an alkali metal salt, a quaternary ammonium salt, or a mixture thereof. The products of the invention are pourable liquid urethane-forming polyols at room temperature.

Abstract: The invention relates to a process for reacting RO--CH.sub.2 --OR formaldehyde acetals with carbon monoxide in the liquid phase on an acid organic ion exchange material as catalyst. The main products are ether-esters, RO--CH.sub.2 --COOR, of hydroxyacetic acid (glycolic acid).

Abstract: The invention declares new chiral, optically active compounds of the general formula ##STR1## wherein a 5 or 6 membered lactol ring (E), with X and Y meaning (CR.sup.1 R.sup.2).sub.n, with n=0 to 2 and R.sup.1, R.sup.2 =H, lower alkyl or aryl in any combination which does not impair the anomeric selectivity of I in forming acetals, is fused in a stereospecific manner to a bicyclo[2.2.

Abstract: A process is disclosed for the production of alkyl-5-substituted-3-furoate compounds of the general formula: ##STR1## in which R.sub.1 is an unsubstituted or substituted aryl which substituent will not affect the reaction, such as phenyl and R.sub.2 is a lower alkyl having 1 to 6 carbon atoms employing alkyl-4-oxo-5-substituted-pentanoate as a starting material.

Abstract: This invention provides tobacco compositions which contain a hydroxy-substituted carboxylate compound as a flavorant additive.In one of its embodiments, this invention provides tobacco compositions which contain a hydroxy-substituted alkanoate flavorant additive such as ethyl 2-(2-butyl)-3-hydroxy-3-methyl-3-phenylpropionate: ##STR1## Under smoking conditions the above illustrated hydroxy-substituted alkanoate additive and its pyrolysis products flavor the mainstream and sidestream smoke.

Abstract: 6-Phenyl-, phenylalkyl- and phenylethenyl-4-hydroxytetrahydropyran-2-ones in the 4(R)-trans stereoisomeric forms are potent inhibitors of cholesterol synthesis by virtue of their ability to inhibit the enzyme, 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

Abstract: Novel bicyclo [2,2,1] heptanes and hept-2Z-enes are substituted at the 5-position by a 6-carboxyhex-2-enyl group or a modification thereof, and at the 6-position by an aldoxime or ketoxime group which is O-substituted by an aliphatic hydrocarbon residue, an aromatic residue, or an aliphatic hydrocarbon residue substituted directly or through an oxygen or sulphur atom by an aromatic residue. Such compounds may be prepared by the action of an oximating agent on an intermediate which is substituted at the 6-position by an aldehydic or ketonic carbonyl group. The compounds are of value for use in pharmaceutical compositions particularly in the context of the inhibition of thromboxane activity.

Abstract: Prostaglandin and prostacyclin compounds which are fluorine substituted in any one or more of the following positions 4,4; 7,7; 10,10; and 5.

Abstract: Substituted phenylalkenoic acids and esters of the formula: ##STR1## having useful pharmaceutical activity and processes for their preparation are disclosed.

Abstract: Compounds of the formula ##STR1## wherein the 9-chlorine atom can be in the .alpha.- or .beta.-position,R.sub.1 is OR.sub.2, or NHR.sub.3 wherein R.sub.3 is H or the acyl group ofa C.sub.1-15 hydrocarbon carboxylic or sulfonic acid;A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH--,B is --CH.sub.2 --CH.sub.2 --,trans--CH.dbd.CH--, or --C.tbd.C--, ##STR2## wherein the OH-group in each case can be in the .alpha.- or .beta.-position, and can be etherified or esterified by tetrahydropyranyl, tetrahydrofuranyl, .alpha.-ethoxyethyl, trimethylsilyl dimethyl, tert-butylsilyl, tribenzylsilyl, acetyl, propionyl, butyryl or benzoyl;D and E together represent a direct bond orD is a straight-chain or branched alkylene group of 1-10 carbon atoms, optionally substituted by fluorine, andE is oxygen or sulfur or a direct bond, andR.sub.4 is hydroxy or hydroxy etherified or esterified as defined for W above;R.sub.5 is a C.sub.1-10 hydrocarbon aliphatic group; a C.sub.

Abstract: The subject matter of the invention is the new 2-azido-3-benzyloxy-propionic acid benzyl ester which is a valuable intermediate product for the production of D,L-serine or derivatives of D,L-serine. The new compound is produced by reacting 2-chloroacrylonitrile with twice the molar amount of benzyl alcohol to form 3-benzyloxy-2-chloropropionic acid imino benzyl ester, saponifying this with acid to form 3-benzyloxy-2-chloropropionic acid benzyl ester, and finally exchanging the chlorine atom by means of an alkali metal azide in the presence of a phase transfer catalyst for an azido group.

Abstract: Polymeric ethylene oxide/propylene oxide or ethylene oxide/butylene oxide ether carboxylic acids of the formula ##STR1## wherein R denotes methyl or ethyl, preferably methyl, A denotes hydrogen or a metal cation, preferably Na.sup.(+) or K.sup.(+), X and Z together denote a number from 2 to 360, preferably from 2 to 140, y denotes a number from 15 to 70, preferably from 25 to 70 and n denotes a number from 1 to 10, a process for their preparation and their use as surfactants.

Abstract: This disclosure describes novel 16-aryloxy-17,18,19,20-tetranoprostanoic acids and derivatives thereof useful as bronchodilators and as hypotensive and contraceptive agents.

Abstract: Novel compounds of the formulae ##STR1## wherein R represents lower alkyl or lower alkoxy, A represents --CH.sub.2 --, --CO-- or ##STR2## n represents an integer of 1 to 8, X represents hydrogen or hydroxyl which may be protected and Y represents hydroxyl which may be protected, and their esters show an excellent action on the lysosomal membranes of cells, and exhibit excellent pharmacological activities such as physiologic host defense control activity, especially immuno-potentiating activity.

Abstract: 7-arylhept-5-ynoic acids and derivatives thereof are anti-allergy and anti-inflammatory agents. As such, they are useful in the treatment of allergy-caused diseases, particularly chronic obstructive lung diseases.

Abstract: New process for making esters of .alpha.-hydroxymethylene arylacetic acid from the corresponding arylacetic acid ester by conversion with an alkali alcoholate and carbon monoxide. The resulting hydroxy methylene compound can be obtained from the resulting alkali salt by release with an acid.

Abstract: Compounds having the formula ##STR1## R.sub.1 is hydrogen, benzyl or an ester moiety; Y is --CH(R.sub.2 ")CH(R.sub.2)-- or--CH(R.sub.3)CH.sub.2 --;R.sub.2 " is hydrogen or methyl;R.sub.2 is OH or X-substituted (C.sub.1-6)alkyl;R.sub.3 is OH, cyano or X-substituted (C.sub.1-3) alkyl;X is --OR.sub.6, --SR.sub.6, --S(O)R.sub.6, --S(O).sub.2 R.sub.6, --NR.sub.6 R.sub.7, --COOR.sub.7, --CONR.sub.7 R.sub.8 or oxo;with the proviso that when X is --NR.sub.6 R.sub.7, --COOR.sub.7 or --CONR.sub.7 R.sub.8, said group is located on the terminal carbon atom of R.sub.2 or R.sub.3 ;R.sub.6 is hydrogen, (C.sub.1-6)alkyl or acetyl;each of R.sub.7 and R.sub.8 is hydrogen or (C.sub.1-6)alkyl;s is an integer of 1 or 2;with the proviso that when R.sub.6 is acetyl, R.sub.7 is hydrogen and X is other than S(O)R.sub.6 or S(O).sub.2 R.sub.6 ;Z--W is alkyl, phenylalkyl or pyridylalkyl which can have an oxygen atom as part of the alkyl chain, and their use as CNS agents, antidiarrheals and antiemetics.

Abstract: Novel bicyclo [2,2,1] heptanes and hept-2Z-enes are substituted at the 5-position by a 6-carboxyhex-2-enyl group or a modification thereof, and at the 6-position by an aldoxime or ketoxime group which is O-substituted by an aliphatic hydrocarbon residue, an aromatic residue, or an aliphatic hydrocarbon residue substituted directly or through an oxygen or sulphur atom by an aromatic residue. Such compounds may be prepared by the action of an oximating agent on an intermediate which is substituted at the 6-position by an aldehydic or ketonic carbonyl group. The compounds are of value for use in pharmaceutical compositions particularly in the context of the inhibition of thromboxane activity.

Abstract: The present invention provides novel substituted heptadeca-5,9- and 5,10-dienoic acid and similar fatty acid compounds which are derivatives of certain prostaglandins and are potent thromboxane A.sub.2 inhibitors. By virtue of this pharmacological property, they represent useful pharmacological agents for a wide variety of purposes.

Abstract: The disclosure relates to 9.beta.-aryloxy prostane derivatives, for example 16-(3-chlorophenoxy)-11.alpha.,15.alpha.-dihydroxy-16-methyl-9.beta.-pheno xy-18,19,20-trinor-5-cis,13-trans-prostadienoic acid, which possess high activity as abortifacients, cervical softeners, inducers of parturition or inhibitors of gastric acid production in mammals. These properties are typical of prostaglandin analogues of the E series, but chemically the new 9.beta.-aryloxy prostane derivatives are prostaglandin F series analogues and are therefore more stable than the E series analogues previously used for the above purposes. The new derivatives are manufactured by known analogy processes, and are formulated in conventional manner.

Abstract: The process is for the manufacture of phenoxylactic acids and their derivatives of the general formula: ##STR1## (in which R.sub.1 and R.sub.2, identical or different, can represent hydrogen atoms, methyl residues, methoxy groups or halogens; Y represents an OH or O--CO--R.sub.3 group with R.sub.3 representing either an aliphatic residue possibly substituted by a halogen, or an aromatic residue possibly substituted on the nucleus by one or several methyl, methoxy, halogen groups or lastly a heterocyclic group; Z represents OH group or an ##STR2## with R.sub.4 representing an alkyl or aryl radical and R.sub.5 hydrogen or an alkyl radical, NR.sub.4 R.sub.5 possibly also representing the morpholinyl radical). A cyanhydrin is subjected to a Ritter reaction (reaction with tert. butanol or isobutene in the presence of an acid).

Abstract: A method for the asymmetric hydrogenation of .alpha.-ketoesters which comprises subjecting an .alpha.-ketoester containing an .alpha.-ketoester grouping of the formula: --CO--COO-- to assymmetric hydrogenation in the presence of a platinum-alumina catalyst modified with a solution of a cinchona-alkaloid.

Abstract: Prostaglandin and prostacyclin compounds which are fluorine substituted in any one or more of the following positions, 4,4; 7,7; 10,10; and 5.

Abstract: 7-[5-oxo-3-hydroxy-2-(3-substituted)-3-hydroxypropyl)-1-cyclopentene]-hepta noic acids having the following general formula ##STR1## wherein X is oxygen or hydroxyl, R.sub.1 and R.sub.3 are independently hydrogen or methyl, and R.sub.2 is --(CH.sub.2)n-Y where n is an integer from 0 through 4 inclusive, and Y is phenyl, or a cycloalkyl group having 4 to 6 carbon atoms. Said acids as well as certain derivatives thereof are useful as nasal decongestants, inhibitors of gastric secretion, inhibitors of platelet aggregation, blood additives, smooth muscle stimulators, hypotensive agents, labor inducers, and in controlling ovulation.

Abstract: Fluoro-prostaglandin compounds are disclosed, such as, for instance, 18,19,20-trinor-17-cyclohexyl-13-14-dehydro-16(S,R)-fluoro-PGF.sub.2.alpha ..The fluoro-prostaglandins of the present invention have the same therapeutical uses as natural prostaglandins, but have the advantage of being resistant to the enzyme 15-prostaglandin dehydrogenase, and also exhibit a more selective therapeutical action. Certain of the compounds of the present invention exhibit very favorable luteolytic and antiulcer activity.

Abstract: Prostaglandin-type compounds with a phenoxy or substituted-phenoxy substituent at the C-16 position are disclosed, with processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: Prostaglandin-type compounds with a phenoxy or substituted-phenoxy substituent at the C-16 position are disclosed, with processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.

Abstract: Zwitterionic surfactant compounds are made readily biodegradable in the environment by the inclusion of a biochemically and/or hydrolytically labile chemical linkage located between the cationic and anionic charge centers of the compounds and anywhere from the second to the tenth atom distant from the cationic charge center. The biodegradable linkage is preferably an ester or amide. The alkoxylated zwitterionic surfactants herein exhibit outstanding particulate soil removal performance and are also effective in removing oily soils from fabrics, in addition to being readily biodegradable. Also described are detergent compositions containing the zwitterionic surfactants, and, optionally containing cosurfactants and detergent builders.

Abstract: Acyl-substituted phenyl esters of prostacyclin-type compounds, for example the 4-acetylphenyl ester of prostacyclin (PGI.sub.2) illustrated by the formula ##STR1## and including esters of the isomeric 6-hydroxy-PGI.sub.2 and 6-keto-PGF.sub.1.alpha. compounds, said esters having pharmacological activity. Processes for preparing them and the appropriate intermediates are disclosed.

Abstract: 3-Hydroxylbenzyl compounds of formula, ##STR1## in which each of R.sub.1, R.sub.2 and R.sub.3 is a hydrocarbon group, e.g. alkyl, R.sub.4 is hydrogen or alkyl, or forms with R.sub.1 --CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.2 --, and Z is either an oxygen- or sulphur-containing group featuring at least one ester or amide moiety, or a disubstituted amino group, Z being bound to the rest of the molecule via the oxygen or sulphur atom, or nitrogen atom, respectively, are useful as antioxidants. Organic materials which are susceptible to the degradative effects of oxygen are treated with one or more of such compounds, e.g. by incorporation into the body of the organic material, in order to be stabilized against such effects.

Abstract: Novel benzyl ethers of cyclic 1,1-diols, of the formula ##STR1## wherein R.sup.1 is phenyl or substituted phenyl,R.sup.2 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl or --CHX--R.sup.1,X is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, phenyl or substituted phenyl,Y and Y' are individually selected from hydrogen, alkyl, phenyl and substituted phenyl andA is saturated or unsaturated alkylene or substituted alkylene;have been found outstandingly effective as herbicides, particularly as selective herbicides.

Abstract: The present invention concerns prostaglandins having a cyclopropane ring in the 2,3 position.

Abstract: Substituted acetate compounds represented by the formula ##STR1## which are useful as pesticides and pesticidal composition containing the substituted acetate compounds as active ingredients, as well as processes for preparing the compounds and the compositions are disclosed.

Abstract: The present invention relates to a process for the preparation of aromatic or furyl substituted olefins, which comprises reacting an olefinic compound with an aromatic compound or furan compound in the presence of carbon monoxide by using a rhodium carbonyl complex as a catalyst to form a corresponding aromatic or furyl substituted olefin.

Abstract: The present invention provides novel thromboxane analogs and intermediates. Particularly, the present invention provides novel 11a-homo-PG intermediates for preparing 11a-methano TXA.sub.2 compounds.

Abstract: This invention provides new mono-deuterated prostaglandins having prolonged uterotonic activity.

Abstract: Laundry detergent compositions containing no phosphate or low levels of phosphate materials and specific mixtures of selected nonionic surfactants and selected cationic surfactants are disclosed. The nonionic/cationic surfactant mixtures are formulated to have "cloud point" characteristics and, preferably, reduced cationic monomer concentrations as defined herein. These compositions are unusually effective in removing greasy and oily soils and body soils from fabrics; they are also effective in the removal of particulate soils. A process is disclosed for laundering fabrics using compositions containing nonionic surfactants and cationic surfactants.

Abstract: 3,5-Dihydroxypentanoic ester derivatives of formula (I): ##STR1## wherein: A represents an alkylene group which is optionally substituted by one or more alkyl groups, or an alkenylene group;Z represents a substituted or unsubstituted aryl or aryloxy group; andR represents a C.sub.1 -C.sub.4 alkyl group) may be prepared by reacting a dianion of an acetoacetic ester with an aldehyde of formula Z-A-CHO (wherein A and Z are as defined above) and then reducing the resulting compound. These 3,5-dihydroxypentanoic ester derivatives have antihyperlipaemic activity and are thus valuable pharmaceuticals.

Abstract: 11-Substituted prostaglandins E.sub.1, E.sub.2 and F.sub.2.alpha. useful as cardiovascular agents and as agents for inducing labor in pregnant females and for the termination of pregnancy and a process for preparing these prostaglandins.

Abstract: Compounds of the general formula I ##STR1## in which R.sub.1 and R.sub.5 independently of one another denote hydrogen or lower alkyl, one of R.sub.2 and R.sub.3 denotes hydroxyl and the other denotes alkyl, cycloalkyl or aralkyl, R.sub.4 denotes hydrogen or, if R.sub.3 denotes hydroxyl, additionally also denotes alkyl, cycloalkyl or aralkyl, X denotes a group ##STR2## wherein R.sub.8 is alkyl, aralkyl or phenyl and R.sub.9 is alkyl, aralkyl, phenyl or the group ##STR3## or R.sub.9 and R.sub.8 together are alkylene, Y.sub.1 and Y.sub.2 independently of one another denote oxygen or sulphur, p denotes 1 or 2, q denotes 0 or 1, with the proviso that p+q=2, and R.sub.6, if q is 0, denotes alkyl, cycloalkyl, aralkyl or thiaalkyl, in which case Y.sub.1 is linked to a carbon atom in the thiaalkyl radical which does not carry a further hetero-atom, or denotes oxaalkyl, in which case Y.sub.

Abstract: Prostaglandin derivatives having a 19,20-didehydro, a 19-hydroxy, or a 19-keto feature are disclosed, including processes for preparing them and the appropriate intermediates.A typical 19-hydroxy compound of this invention is 19-hydroxy-19-methyl-PGF.sub.2.alpha.

Abstract: This disclosure describes 11-deoxy-11-substituted members of the E.sub.2, F.sub.2, E.sub.1, F.sub.1, dihydro E.sub.1 and dihydro F.sub.1 prostaglandin series which are useful as hypotensive agents and as anti-ulcer agents.

Abstract: A method of synthesizing 1RS,4SR,5RS-4-(4,8-dimethyl-5-hydroxy-7-nonen-1-yl)-4-methyl-3,8-dioxabicy clo [3.2.1]octane-1-acetic acid. The acid is a derivative of the natural product zoapatanol, one of the active ingredients in the zoapatle plant, and is active as a utero-evacuant agent.